LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
1W: +1.1%
1M: -18.8%
3M: -21.6%
YTD: +51.7%
1Y: +59.6%
3Y: +5.2%
5Y: -46.8%
$1.82
+0.00 (+0.00%)
Weekly Expected Move ±8.3%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
23 relationships23
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-07-29
Earliest Filing
2026-02-02
Latest Filing
investor: 18
partner: 4
licensee: 1
Counterparties (Filed by LXRX)
23 relationshipsCompanies named in LXRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Underwriter for the public offering of common stock | 2026-02-02 | View |
| Piper Sandler & Co. | PIPR | partner | Underwriter for the public offering of common stock | 2026-02-02 | View |
| Artal Participations S.à r.l. | — | investor | Investor in the concurrent private placement and preferred stock purchase | 2026-02-02 | View |
| Invus Public Equities Advisors, LLC | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Invus Global Management, LLC | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Invus US Partners LLC | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Invus Advisors, L.L.C. | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Invus Public Equities, L.P. | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Invus, L.P. | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Siren, LLC | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Ulys, L.L.C. | — | investor | Investor in the concurrent private placement | 2026-02-02 | View |
| Raymond Debbane | — | investor | Individual investor in the concurrent private placement | 2026-02-02 | View |
| Novo Nordisk A/S | NVO | partner | Entered into an Exclusive License Agreement for the worldwide development, manufacture, and commercialization of LX9851. | 2025-03-28 | View |
| Viatris Inc. | VTRS | licensee | Exclusive license agreement for development and commercialization of sotagliflozin outside the US and Europe. | 2024-10-16 | View |
| Invus, L.P. | — | investor | Accredited investor participating in the private placement of Series A Convertible Preferred Stock. | 2024-03-11 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Company's open market sale of common stock. | 2023-12-29 | View |
| Artal International S.C.A. | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
| Artal Group S.A. | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
| Artal International Management S.A. | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
| Invus Advisors, L.L.C. | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
| Invus Public Equities, L.P. | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
| Invus, L.P. | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
| Invus US Partners LLC | — | investor | Private placement purchaser of common stock | 2022-07-29 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-30 | Material Agreement; Unregistered Equity Sales; Bylaws Amendment; Shareholder Vote; Exhibits | Agreement | View |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2026-01-29 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-11-10 | Other Events | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-28 | Other Events | View | |
| 2025-07-03 | Other Events | View | |
| 2025-06-03 | Entry into Material Definitive Agreement; Submission of Matters to a Vote of Security Holders; Finan | Agreement | View |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-28 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-07 | Notice of Delisting or Transfer | View | |
| 2025-01-02 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-11-22 | Costs Associated with Exit or Disposal Activities | View | |
| 2024-11-20 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR